

(Final Result Brief for the year ended 31 December 2024)

First - General Information:

Name of the company: Gulf Pharmaceutical Industries PSC (Julphar)

Date Establishment: 1980

Paid up capital: 1,155,227,811

Subscribed capital: 1,155,227,811

Authorized capital: 1,155,227,811

Chairman of the Board: Sheikh Saeqer Bin Humaid Al Qassimi

Chief Executive Officer: Basel Nimer Ali Ziyadeh

Name of the external auditor: M/s Ernst & Young

Mailing address: P.O. Box 997

Tel: +971 7 246 1461

Fax: +971 7246 2462

E – mail: julphar@emirates.net.ae

Second - Preliminary Results (000 AED) :

	<u>2024</u>	<u>2023</u>
Total Assets	2,431,100	2,453,900
Shareholders' Equity	798,700	794,200
Revenues from continuing operations	1,312,500	1,277,500
Net Operating Profit/(loss) from continuing operations	79,700	(19,500)
Net profit/loss) for the year	40,500	(98,500)
EBITDA from continuing operations	144,900	47,500
Earnings per share (fills per share)	3.5	(8.6)

Summary of the company's performance for the last fiscal year.

The Company's revenues reached AED 1,312.5m, reflecting 2.7% growth in the reported currency from continued operation compared to the same period last year, and 4% growth on a constant currency basis.

Profitability sustains its steady growth trend. The company reported profits of AED at +40.5m, a sharp improvement from AED -98.5m previous year. EBITDA from continued operations tripled versus same period last year and reached AED 144.9 m, exhibiting the successful execution of the strategic and operational efficiency initiatives.

These results highlight our continued progress in maintaining a strong balance between business investments, a solid capital structure, and building shareholder value. Our strong market position is reinforced by the dedication of our team across our operating regions.

The name of the chairman of the company	Sheikh Saqer Bin Humaid Al Qassimi
Signature and Date	13/02/2025
Company's Seal	